Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If that is Romanian New Leu currency reported that order is valued between $18,500 and $55,700. That would also indicate a per kit price of $2,000.
Also here:
II.2.1) Cantitatea totala sau domeniul:
Nr. lot Denumire produs U.M. CANT MIN/AC 2 ani CANT MAX/AC 2 ani VAL MIN/AC 2 ani VAL MAX/AC 2 ani
4 Cytosorb kit 1 3 6.700,00 20.100,00
SABAI is right, there are many biotechs that trade at 250million+ market cap and have little to no revenue. Companies like this don't necessarily trade on revenue. They trade on potential market capitalization and growth. Don't be surprised to see CTSO pull in 1 million in the third or fourth quarter and trade at 300-400 million market cap. Biotech stocks that are just starting to commercialize their products rarely trade as you would expect them to.
CytoSorbents PT Raised to $1.00 at Brean Capital (CTSO)
Posted by Stuart Ham on Apr 1st, 2014 // No Comments
Equities research analysts at Brean Capital hoisted their price target on shares of CytoSorbents (NASDAQ:CTSO) to $1.00 in a research note issued to investors on Tuesday, Analyst Ratings.Net reports. Brean Capital’s target price suggests a potential upside of 334.78% from the stock’s previous close.
Shares of CytoSorbents (NASDAQ:CTSO) opened at 0.23 on Tuesday. CytoSorbents has a one year low of $0.08 and a one year high of $0.35. The stock’s 50-day moving average is $0.24 and its 200-day moving average is $0.16. The company’s market cap is $56.8 million.
CytoSorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Monday, March 31st. The company reported ($0.01) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.01). Analysts expect that CytoSorbents will post $-0.03 EPS for the current fiscal year.
Separately, analysts at Zacks reiterated an “outperform” rating on shares of CytoSorbents in a research note on Friday, January 17th. They now have a $0.50 price target on the stock.
CytoSorbents Corporation, formerly MedaSorb Technologies Corporation, is a development-stage therapeutic medical device company.
Too bad we're not actually on the NASDAQ yet.
They've already put out an estimate. I believe it was about $850k for the first full year of commercialization. Including non-dilutive funds from govt grants and other sources they have $2million+ in revenue for the fiscal year. That initially pushed the stock to .30. Confirming the results with the next 10k and giving a positive outlook should keep things in the .20s. First quarter financials will be the thing to look at. Continued increase in sales of cytosorb vs fourth quarter 2013 will push the pps up.
$597k. A drop of ~$130k from last quarter.
My TD account chart shows it happened Wednesday afternoon. What chart site are you using?
Vans,
We hit that golden cross on Wednesday. Any insight into how the timing of that relates to earnings reports with other companies that have also had that indicator?
Cheers,
Cougfan
FY 2014 MDA budget request: $7.68 billion with most of that for R&D. Starts on pg. 54. That's a lot of potential $$$ for fsc5962 parts.
http://www.fas.org/sgp/crs/natsec/R43323.pdf
Some superbowl related counterfeiting news.
http://espn.go.com/nfl/playoffs/2013/story/_/id/10375831/super-bowl-xlviii-feds-seize-216m-counterfeits
On a 2014 biotech stock watch list
http://jutiagroup.com/20140116-biotech-watchlist-2014-sound-science-innovative-ideas-and-a-sprinkle-of-pixie-dust/
Nice bit in the WSJ. Hopefully this sparks some interest.
http://online.wsj.com/article/PR-CO-20140115-911339.html
Just another example of how large the market potential for APDN is. Let the table on page 13 sink in for a minute. So much opportunity for DNA marking.
http://www.ficci.com/spdocument/20307/FICCI-Anti-piracy-paper.pdf
Apologies if this has already been posted.
PR released in November just posted to APDN website dated January 8, 2014. Perhaps a sign they know the mandate expansion is a sure thing?
http://www.adnas.com/sites/default/files/securing_industry_1-2014.pdf
The cost of the license is clear, but what is the cost of the actual DNA marking material. This has the potential to generate much more revenue than the actual license. If APDN marks cotton for 5 years or whatever the agreement was that's $250k, but when we're talking about marking millions of kilograms of cotton I see a lot of $$$$$$$$ in consumable material being sold. I want to know what the price of that consumable DNA material is.
A huge question mark with regard to recurring revenue is how much does it cost to mark a chip/circuit/component/bushel of cotton etc. If APDN is selling DNA marks by the liter for say $50k and that quantity can mark 1 million or more components then that's what we need to focus on and ask about. We've been focused on revenue from startup costs and yearly renewals for new markers, but there has to be some kind of revenue generated from a price per component/bushel or whatever. Many of these companies will need to order more and more DNA marking material as production goes on throughout the year and I believe that will be a big source of revenue.
Let's say one microchip requires a minimum ten nanograms of DNA to be properly marked. If APDN sells 1 liter of marking solution with a concentration of 1 microgram per milliliter a company can mark 100,000 microchips with that 1 liter. How much does that 1 liter of marking solution cost? That is the key to figuring out recurring revenue based on some of these awarded contracts from the DLA. I don't know exactly how microchips are marked so this is all hypothetical, but I think the point is clear.
Does anyone have information on this?
Cheers,
Cougfan
One thing that hasn't been talked about much is the cash and cash equivalents for end of year 2013: $6,360,301 compared to $724,782 for 2012. Total assets over $7 million end of year 2013 compared to $1.1 million for 2012. Two things come to mind from this: Whatever money they have is managed fairly well and the company is positioned nicely for any setup cost they might incur with new contracts this quarter and next AND they should have enough capital to get through most of FY 2014 without funding via share dilution. That's great news for investors and I think the next two quarterly calls will be a pleasant surprise in terms of cost vs income.
New to the site and excited to find other people so invested in APDN. Great to see some good news this week. I've been patiently waiting for several years like many of you. Hopefully in the next few months (or weeks with a good earnings report) we will see a big increase in pps and more people will realize this is a great stock. If the DLA expands their mandate to cover other FSC 5XXX items and we see revenue at 1mil+ per quarter how long do you think it will be until we can get out of the OTC market and avoid some of this pps manipulation? Obviously expenses need to go down, but we're headed in the right direction and I think we'll get out of the red sooner than the Zacks report estimates.
Cheers,
Cougfan